What did @doctormaloney actually say?
The claim is this: if you're losing weight on semaglutide, you don't need to follow the standard dose-escalation schedule. The creator argues that most patients respond well on lower doses, that increasing the dose when things are working is like upping a painkiller when the pain is already gone, and that staying on the lowest effective dose will make it easier to stop the medication later without regaining weight. That last part is the one worth scrutinizing most carefully.
The painkiller analogy sounds intuitive. The weight-regain-at-max-dose claim is where things get more complicated, and where this video risks misleading 1.4 million viewers.
Does the science back this up?
Partially, but not in the way the creator implies. The idea that some patients can achieve meaningful weight loss on lower doses is real and documented. The claim that weight regain after stopping is specifically caused by being on a high dose is not supported by the evidence.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that participants regained roughly two-thirds of their lost weight within a year of stopping semaglutide 2.4mg. But that weight regain was observed across the board, not just in people who had escalated to max doses. It reflects the underlying biology of obesity as a chronic condition, not a dosing artifact. The drug stops suppressing appetite and slowing gastric emptying, and body weight rebounds toward its defended set point. Dose at discontinuation was not identified as a predictor of regain magnitude in that data.
What did they get wrong (or right)?
Let's give credit where it's due. The idea of using the lowest effective dose is a legitimate clinical principle. There is real heterogeneity in how patients respond to semaglutide, and some people do lose significant weight without reaching the 2.4mg maintenance dose used in the STEP trials. A 2022 analysis by Rubino et al. in JAMA confirmed sustained dose-response benefits, but individual variation exists and clinical judgment matters.
What the creator gets wrong is the framing around weight regain. Saying that people in studies regained weight because they were on the max dose reverses the actual causality. They were on the max dose because that's the protocol used in efficacy trials. They regained weight because the drug was stopped, full stop. There is no published evidence showing that patients on lower maintenance doses regain less weight after discontinuation. That claim is not just unproven, it's potentially harmful if it leads patients to deprioritize dose optimization without a real clinical rationale.
The painkiller analogy also breaks down under pressure. Pain relief is an endpoint. Weight loss trajectory is a process that can stall, plateau, or reverse. These are not equivalent clinical situations.
What should you actually know?
Dose escalation in semaglutide protocols exists for a reason. The titration schedule is designed to minimize gastrointestinal side effects, not just to chase a higher number. Stopping escalation because you're losing weight at week four or eight might work for some patients. It might also mean you plateau earlier and miss the additional metabolic benefits seen at higher doses, including glycemic control improvements that matter even when weight loss is the primary goal.
The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed that continued treatment at 2.4mg maintained weight loss over two years, while earlier dose-capping data is limited. If your weight loss stalls on a lower dose, the clinical standard is to consider escalation, not to assume the lower dose is working well enough.
The right approach is a conversation with your prescriber, based on your response, tolerability, and goals. A TikTok video, however well-intentioned, is not that conversation.
Is @doctormaloney the only one saying this?
The creator repeats twice that they're "like the only doctor online" discussing this. That framing deserves some skepticism on its own. Individualized dosing and minimum effective dose principles are standard in clinical pharmacology. The specific claim about dose level predicting post-discontinuation weight regain, however, does appear to be the creator's own interpretation, and it is not backed by peer-reviewed evidence. Being the only person saying something is not the same as being the only person who figured it out. Sometimes it just means the claim doesn't hold up to scrutiny.